Last reviewed · How we verify

Novel CAR-T

Timmune Biotech Inc. · Phase 1 active Biologic

Novel CAR-T is a Biologic drug developed by Timmune Biotech Inc.. It is currently in Phase 1 development.

At a glance

Generic nameNovel CAR-T
SponsorTimmune Biotech Inc.
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Novel CAR-T

What is Novel CAR-T?

Novel CAR-T is a Biologic drug developed by Timmune Biotech Inc..

Who makes Novel CAR-T?

Novel CAR-T is developed by Timmune Biotech Inc. (see full Timmune Biotech Inc. pipeline at /company/timmune-biotech-inc).

What development phase is Novel CAR-T in?

Novel CAR-T is in Phase 1.

Related